Glaukos Corporation
Index- P/E- EPS (ttm)-0.61 Insider Own2.40% Shs Outstand47.05M Perf Week1.81%
Market Cap1.87B Forward P/E- EPS next Y-1.30 Insider Trans0.00% Shs Float45.50M Perf Month-24.75%
Income-27.70M PEG- EPS next Q-0.44 Inst Own93.40% Short Float3.96% Perf Quarter-26.58%
Sales293.70M P/S6.37 EPS this Y60.50% Inst Trans-0.63% Short Ratio3.74 Perf Half Y-14.66%
Book/sh12.70 P/B3.14 EPS next Y25.30% ROA-2.60% Target Price54.29 Perf Year-46.65%
Cash/sh8.85 P/C4.50 EPS next 5Y8.00% ROE-4.70% 52W Range33.33 - 87.24 Perf YTD-10.37%
Dividend- P/FCF- EPS past 5Y-60.40% ROI-3.50% 52W High-54.34% Beta1.56
Dividend %- Quick Ratio8.40 Sales past 5Y20.80% Gross Margin77.20% 52W Low19.50% ATR2.71
Employees727 Current Ratio8.80 Sales Q/Q-0.40% Oper. Margin-3.80% RSI (14)39.43 Volatility4.75% 7.07%
OptionableYes Debt/Eq0.00 EPS Q/Q130.10% Profit Margin-9.40% Rel Volume0.54 Prev Close38.94
ShortableYes LT Debt/Eq0.59 EarningsMay 04 AMC Payout- Avg Volume481.56K Price39.83
Recom2.50 SMA20-3.91% SMA50-22.57% SMA200-20.52% Volume262,240 Change2.29%
Feb-03-22Upgrade William Blair Mkt Perform → Outperform
Jan-19-22Upgrade Wells Fargo Underweight → Equal Weight $56
Jan-18-22Upgrade BTIG Research Neutral → Buy $61
Nov-03-21Upgrade Stephens Equal-Weight → Overweight $68
Jul-26-21Downgrade Stephens Overweight → Equal-Weight $70
Jul-20-21Downgrade Wells Fargo Equal Weight → Underweight $41
Jul-14-21Downgrade William Blair Outperform → Mkt Perform
Jul-14-21Downgrade Oppenheimer Outperform → Perform
Apr-08-21Upgrade Oppenheimer Perform → Outperform $100
Jan-29-21Downgrade Piper Sandler Overweight → Neutral $70 → $80
Dec-16-20Upgrade Citigroup Sell → Neutral $50 → $72
Dec-09-20Initiated Oppenheimer Perform
Nov-17-20Upgrade Wells Fargo Underweight → Equal Weight $68
Oct-08-20Downgrade JP Morgan Neutral → Underweight $50
Jun-15-20Initiated Jefferies Hold $44
Mar-05-20Initiated Citigroup Sell $40
Feb-28-20Downgrade JP Morgan Overweight → Neutral $55
Jan-06-20Upgrade Berenberg Hold → Buy $60 → $65
Dec-12-19Downgrade Wells Fargo Outperform → Underperform
Sep-30-19Downgrade BofA/Merrill Buy → Underperform
May-20-22 07:00AM  
May-10-22 11:04AM  
May-04-22 06:45PM  
May-03-22 11:13AM  
Apr-21-22 07:00AM  
Apr-20-22 07:00AM  
Apr-13-22 07:00AM  
Mar-30-22 11:33AM  
Mar-14-22 07:00AM  
Feb-24-22 04:41AM  
Feb-23-22 11:07AM  
Feb-22-22 06:15PM  
Feb-15-22 03:01PM  
Feb-07-22 04:15PM  
Feb-01-22 07:00AM  
Jan-12-22 05:47AM  
Jan-11-22 04:10PM  
Jan-10-22 05:43AM  
Jan-06-22 04:10PM  
Dec-29-21 11:27AM  
Dec-20-21 04:15PM  
Dec-17-21 08:38PM  
Dec-11-21 05:38AM  
Dec-09-21 05:38PM  
Dec-07-21 08:50AM  
Nov-30-21 10:15AM  
Nov-11-21 07:00AM  
Nov-08-21 10:16AM  
Nov-07-21 09:30AM  
Nov-04-21 06:45PM  
Nov-03-21 12:39PM  
Oct-29-21 11:38AM  
Oct-28-21 03:06PM  
Oct-14-21 07:00AM  
Oct-11-21 08:12AM  
Oct-07-21 04:15PM  
Sep-20-21 10:19AM  
Sep-15-21 09:19AM  
Sep-09-21 09:24AM  
Sep-06-21 01:29PM  
Sep-03-21 07:00AM  
Aug-26-21 07:00AM  
Aug-23-21 07:00AM  
Aug-17-21 10:49AM  
Aug-09-21 09:01AM  
Aug-06-21 02:30PM  
Aug-05-21 05:55PM  
Jul-29-21 03:05PM  
Jul-27-21 10:27PM  
Jul-22-21 07:00AM  
Jul-20-21 03:45PM  
Jul-16-21 06:14AM  
Jul-15-21 04:15PM  
Jul-14-21 11:14AM  
Jul-11-21 05:58AM  
Jul-02-21 08:27AM  
Jul-01-21 07:22PM  
Jun-10-21 07:00AM  
Jun-08-21 07:00AM  
Jun-04-21 11:31AM  
May-27-21 07:48AM  
May-25-21 10:21AM  
May-19-21 09:58AM  
May-18-21 06:00PM  
May-12-21 09:43AM  
May-09-21 05:19AM  
May-05-21 08:01PM  
Apr-28-21 12:33PM  
Apr-27-21 07:00AM  
Apr-22-21 07:00AM  
Apr-14-21 04:15PM  
Mar-27-21 11:31AM  
Mar-24-21 03:23AM  
Mar-23-21 09:14AM  
Mar-08-21 07:00AM  
Mar-02-21 07:00AM  
Mar-01-21 04:10PM  
Feb-26-21 11:31AM  
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burns Thomas WilliamChief Executive OfficerAug 06Option Exercise4.44286,8801,273,068635,062Aug 09 08:26 PM